Company intelligence / Profile preview

Next Biomedical

Incheon, Incheon, South Koreanextbiomedical.co.kr ↗

Ownership: Private
Development stage: Other

Overview

Next Biomedical has achieved regulatory clearances in major markets including the US FDA, CE-MDR certification in Europe, Health Canada clearance, Singapore HSA approval, and Japan PMDA approval for its key products. Its lead product Nexpowder is commercially available with global distribution through Medtronic. The company’s pipeline includes additional innovative therapeutic devices targeting unmet needs in hemostasis and vascular embolization.

Therapeutic areas: GastroenterologyRheumatology
Modalities: DeviceDrug delivery systemPolymer-based medical deviceResorbable gelatin microspheres (for embolization)
Industry: Therapeutic Medical Devices

Partnerships

Medtronic (global supply/distribution agreement)

Beyond the preview

Go deeper on Next Biomedical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Next Biomedical.

Explore the full profile